Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Oct 4, 2021
International Plasma Awareness Week 2021: Donate Plasma. Save Lives.
October 4, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the ninth annual International Plasma Awareness Week (IPAW), which will run from Monday, October 4 until Friday, October 8. Nearly 125,000 people in the U.S. with rare diseases, and countless others facing trauma and emergency medical needs every day, rely on medicines that are only available because of the commitment of dedicated plasma donors.
All
Press releases
Oct 4, 2021
International Plasma Awareness Week 2021: Donate Plasma. Save Lives.
October 4, 2021 (Annapolis, MD) — The Plasma Protein Therapeutics Association (PPTA) is proud to mark the launch of the ninth annual International Plasma Awareness Week (IPAW), which will run from Monday, October 4 until Friday, October 8. Nearly 125,000 people in the U.S. with rare diseases, and countless others facing trauma and emergency medical needs every day, rely on medicines that are only available because of the commitment of dedicated plasma donors.
All
Press releases
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Oct 1, 2021
Together toward a broader European plasma donation ecosystem
Strengthening the EU Blood Directive: To meet the needs of patients using plasma-derived medicinal products and plasma donors
All
Advocacy
https://cdn.prod.website-files.com/638f893112c6eac0e46ac576/6453f652d7ca1569557512dc_PPTA%20Position%20Paper%20on%20the%20EU%20BTC%20revision_September2021.pdf
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Oct 1, 2021
Plasmavigilance-Adverse events among US Source plasma donors
Source plasma (SP) is the primary starting material for 87% of plasma-derived medicinal products globally. Plasmavigilance is a program designed to collect, analyze, and monitor donor adverse events (AEs) across the SP collection industry.
All
Publication
https://pubmed.ncbi.nlm.nih.gov/34390267/
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
Sep 23, 2021
Plasma donations remain disappointingly low through ongoing pandemic, risking patients’ lives
The Plasma Protein Therapeutics Association (PPTA) is aware of emerging reports regarding patients not having reliable access to lifesaving plasma-derived therapies used to treat a variety of serious, rare, and chronic conditions caused by missing or deficient proteins in their blood.
All
PPTA statements
No results found